WallStSmart

The Ensign Group Inc (ENSG)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 110442% more annual revenue ($5.06B vs $4.58M). ENSG leads profitability with a 6.8% profit margin vs 3.8%. ENSG earns a higher WallStSmart Score of 57/100 (C).

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34

NIVF

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 3.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued
NIVFUndervalued (+100.0%)

Margin of Safety

+100.0%

Fair Value

$3305.41

Current Price

$2.01

$3303.40 discount

UndervaluedFair: $3305.41Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

NIVF1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

NIVF4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$983,3203/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.6%3/10

ROE of 1.6% — below average capital efficiency

Profit MarginProfitability
3.8%3/10

3.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : NIVF

The strongest argument for NIVF centers on Price/Book.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : NIVF

The primary concerns for NIVF are EPS Growth, Market Cap, Return on Equity. Thin 3.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

ENSG profiles as a growth stock while NIVF is a value play — different risk/reward profiles.

ENSG carries more volatility with a beta of 0.80 — expect wider price swings.

ENSG is growing revenue faster at 20.2% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENSG scores higher overall (57/100 vs 51/100) and 20.2% revenue growth. NIVF offers better value entry with a 100.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

NewGenIvf Group Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

NewGenIvf Group Limited (NIVF) is a prominent provider in the reproductive health sector, specializing in advanced fertility solutions and innovative in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive techniques and addresses the growing global demand for fertility treatments through a well-established network of clinics and strategic partnerships. Positioned for growth within a rapidly expanding market, NIVF is well-equipped to capitalize on emerging opportunities, reinforcing its commitment to helping individuals and couples realize their dreams of parenthood.

Want to dig deeper into these stocks?